The promise of molecular gates and what comes next
Gate Bioscience is developing a new class of medicines designed to eliminate disease-causing proteins at their source. In this episode of "The Top Line," Gate co-founder and CEO Jordi Mata-Fink, Ph.D., discusses the promise of molecular gates, the biotech's expanded partnership with Eli Lilly and its plans to bring the technology into the clinic.
Biotech The promise of molecular gates and what comes next By Marissa Russo, Ayla Ellison Nov 13, 2026 9:58am The Top Line Gate Bioscience small molecules podcast Gate Bioscience is betting that a decades-old biological mechanism could pave the way for a new class of medicines. The biotech is developing small molecules that selectively block disease-causing proteins from passing through a cellular channel called Sec61, causing them to be degraded before they can do harm. The approach could be particularly promising for diseases of the brain, where traditional biologics face significant delivery challenges.
Gate's first publicly disclosed program targets prion disease, but the company sees opportunities across inflammation, fibrosis and other therapeutic areas. In this episode of "The Top Line," Fierce Biotech's Marissa Russo sits down with Gate co-founder and CEO Jordi Mata-Fink, Ph.D., to discuss the science behind the technology, how an expanded partnership with Eli Lilly is helping advance the platform and what's next as Gate prepares to move its first molecular gate drugs into the clinic. To learn more about the topics in this episode: Gate CEO sees expanded $870M pact with Lilly as ‘vote of confidence’ in biotech’s platform The Top Line Gate Bioscience small molecules podcast Biotech
comments(0)
5-min edit window · permanent after that